HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial
HIP ATTACK-2
1 other identifier
interventional
1,100
19 countries
70
Brief Summary
The HIP ATTACK-2 trial is a multicentre, international, parallel group randomized controlled trial to determine whether accelerated surgery for hip fracture in patients with acute myocardial injury is superior to standard care in reducing death at 90 days after randomization. The trial will also assess secondary outcomes at 90 days after randomization: inability to independently walk 3 metres, time to first mobilization (first standing and first full weight bear), composite and individual assessment of major complications (e.g., mortality, non-fatal myocardial infarction, acute congestive heart failure, and stroke), delirium, length of stay, pain, and quality of life.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Nov 2021
Longer than P75 for not_applicable
70 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 3, 2021
CompletedFirst Posted
Study publicly available on registry
February 8, 2021
CompletedStudy Start
First participant enrolled
November 22, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 28, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
May 31, 2027
October 1, 2025
September 1, 2025
5.3 years
February 3, 2021
September 25, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
All cause mortality
Death due to all causes
Within 90 days post randomization
Secondary Outcomes (10)
Ability to independently walk 3 meters
Within 90 days post randomization
Composite of major complications
Within 90 days post randomization
Vascular mortality
Within 90 days post randomization
Nonvascular mortality
Within 90 days post randomization
Myocardial Infarction
Within 90 days post randomization
- +5 more secondary outcomes
Other Outcomes (19)
New clinically important atrial fibrillation or flutter
Within 90 days post randomization
Cardiac revascularization procedure
Within 90 days post randomization
Venous thromboembolism
Within 90 days post randomization
- +16 more other outcomes
Study Arms (2)
Accelerated medical clearance and surgery
EXPERIMENTALAccelerated medical clearance and targeted arrival to the operating room within 6 hours of eligibility criteria met.
Standard surgical care
NO INTERVENTIONHip fracture repair and surgical care according to treating institution guidelines.
Interventions
Rapid medical clearance with targeted arrival to the operating room within 6 hours of eligibility criteria criteria met.
Eligibility Criteria
You may qualify if:
- age ≥45 years;
- diagnosis of hip fracture during working hours with a low-energy mechanism requiring surgery;
- troponin elevation ( at least one troponin measurement above the upper limit of normal occurring from the time of hip fracture to the time of randomization); and
- informed consent.
You may not qualify if:
- taking a therapeutic dose of an anticoagulant for which no reversing agent is available and the anesthesiologist or surgeon believe surgery within 6 hours of eligibility criteria met would not be safe;
- patients on a therapeutic vitamin K antagonist with a history of heparin induced thrombocytopenia (HIT);
- patients with peri-prosthetic fracture, open fracture or bilateral fractures;
- patients requiring an emergency surgery for another reason (e.g., subdural hematoma);
- patients with acute myocardial infarction deemed to be clinically unstable, with a mechanical complication (i.e., acute papillary muscle rupture, ventricular septal defect), ST elevation myocardial infarction, or cardiogenic shock;
- patients refusing consent; or
- patients previously enrolled in HIP ATTACK-2.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (70)
Chandler Regional Medical Center
Chandler, Arizona, 85224, United States
The Regents of the University of California
Davis, California, 95618, United States
Yale New Haven Hospital
New Haven, Connecticut, 06520, United States
Emory University at Grady Memorial Hospital
Atlanta, Georgia, 30322, United States
University of Maryland
Baltimore, Maryland, 20742, United States
Sinai Hospital of Baltimore
Baltimore, Maryland, 21215, United States
Tufts Medical Center
Boston, Massachusetts, 02111, United States
Lahey Hospital and Medical Center
Burlington, Massachusetts, 01805, United States
University of Michigan
Ann Arbor, Michigan, 48109, United States
Mayo Clinic
Rochester, Minnesota, 55905, United States
Bryan Medical Center
Lincoln, Nebraska, 68506, United States
University Medical Center of Southern Nevada
Las Vegas, Nevada, 89102, United States
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, 03756, United States
Montefiore Medical Center
The Bronx, New York, 10467, United States
Cleveland Clinic
Cleveland, Ohio, 44195, United States
Oregon Health and Science University
Portland, Oregon, 97239, United States
St. Luke's University Health Network
Bethlehem, Pennsylvania, 18015, United States
The University of Texas Health Science Center at Houston
Houston, Texas, 77030, United States
University of Wisconsin
Madison, Wisconsin, 53715, United States
The John Hunter Hospital
New Lambton Heights, New South Wales, 2305, Australia
Cliniques Universitaires Saint Luc - University Catholic of Louvain
Woluwe-Saint-Lambert, Brussels Capital, 1200, Belgium
University of São Paulo
São Paulo, São Paulo, 05403010, Brazil
University of Alberta Hospital
Edmonton, Alberta, T6G 2B7, Canada
St. Joseph's Healthcare Hamilton
Hamilton, Ontario, L8N 4A6, Canada
Juravinski Hospital
Hamilton, Ontario, L8V 1C3, Canada
Victoria Hospital
London, Ontario, N6A 5W9, Canada
Markham Stouffville Hospital
Markham, Ontario, L3P 7P3, Canada
Ottawa General Hospital
Ottawa, Ontario, K1H 8L6, Canada
CISSS de Laval
Laval, Quebec, H7M 3L9, Canada
Pontifica Universidad Catolica de Chile
Santiago, RM, 83300024, Chile
Clinica Santa Maria
Santiago, 7520378, Chile
South Karelia Central Hospital
Lappeenranta, 53130, Finland
Tampere University Hospital
Tampere, 33521, Finland
Queen Mary Hospital
Hong Kong, Hong Kong
Bangalore Baptist Hospital
Bangalore, Karnataka, 560024, India
Government TD Medical College
Alappuzha, Kerala, 688005, India
Government Medical College
Trivandrum, Kerala, 695011, India
All India Institute of Medical Sciences (AIIMS)
New Delhi, National Capital Territory of Delhi, 110029, India
JIPMER
Puducherry, Puducherry, 605006, India
Hospital of Perugia
Perugia, Umbria, 06129, Italy
Galliera Hospital
Genova, 16128, Italy
Ospedale San Raffaele S.r.l.
Milan, 20132, Italy
Ospedale Galeazzi SpA
Milan, 20157, Italy
University of Malaya Medical Centre
Kuala Lumpur, 59100, Malaysia
Christus Muguerza del Parque
Chihuahua City, Chihuahua, 31000, Mexico
Cruz Verde Guadalajara
Guadalajara, Jalisco, 44410, Mexico
B and B Hospital
Lalitpur, Bagmati, 44700, Nepal
Deventer Hospital
Deventer, Overijssel, 7416 SE, Netherlands
Stichting OLVG
Amsterdam, Netherlands
Maroof International Hospital
Islamabad, ICT, 44000, Pakistan
Shifa International Hospitals Ltd.
Islamabad, ICT, 44000, Pakistan
Hayat Abad Medical Complex
Peshawar, KPK, 25000, Pakistan
Ghurki Trust Teaching Hospital
Lahore, Punjab Province, 54000, Pakistan
Combined Military Hospital
Rawalpindi, Punjab Province, 46000, Pakistan
Aga Khan University
Karachi, Sindh, 74800, Pakistan
Indus Hospital & Health Network
Karachi, Sindh, Pakistan
SPZOZ Myslenice
Myślenice, Malopolska, 32-400, Poland
King Faisal Specialist Hospital
Riyadh, Riyadh Region, 11211, Saudi Arabia
Stellenbosch University - Tygerberg Hospital
Cape Town, Western Cape, 7505, South Africa
Groote Schuur Hospital
Cape Town, Western Cape, 7925, South Africa
Hospital Universitari Sagrat Cor
Barcelona, Barcelona, 08029, Spain
Hospital Universitari Vall d'Hebron
Barcelona, Barcelona, 08035, Spain
Hospital Clinic of Barcelona
Barcelona, Barcelona, 08036, Spain
Hospital de la Santa Creu I Sant Pau
Barcelona, Barcelona, 08041, Spain
Hospital Universitari Parc Tauli
Sabadell, Barcelona, 08208, Spain
Hospital Sant Camil
Sant Pere de Ribes, Barcelona, 08810, Spain
Hospital Universitario Mutua de Terrassa
Terrassa, Barcelona, 08221, Spain
Hospital Costa del Sol
Marbella, Malaga, 29603, Spain
Hospital Clinico Universitario de Vallad
Valladolid, Valladolid, 47007, Spain
Parc Sanitari Sant Joan de Déu
Barcelona, 08830, Spain
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Flavia Borges, M.D
Population Health Research Institute
- PRINCIPAL INVESTIGATOR
Gerard Slobogean, M.D
University of Maryland, Baltimore
- PRINCIPAL INVESTIGATOR
Robert Feibel, M.D
The Ottawa Hospital
- STUDY CHAIR
PJ Devereaux, M.D
Population Health Research Institute
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 3, 2021
First Posted
February 8, 2021
Study Start
November 22, 2021
Primary Completion (Estimated)
February 28, 2027
Study Completion (Estimated)
May 31, 2027
Last Updated
October 1, 2025
Record last verified: 2025-09
Data Sharing
- IPD Sharing
- Will not share
The Population Health Research Institute (PHRI) is the sponsor of this trial. The PHRI believes the dissemination of clinical research results is vital and sharing of data is important. PHRI prioritizes access to data analyses to researchers who have worked on the trial for a significant duration, have played substantial roles, and have participated in raising the funds to conduct the trial. PHRI balances the length of the research study, and the intellectual and financial investments that made it possible with the need to allow wider access to the data collected. Data will be disclosed only upon request and approval of the proposed use of the data by a Review Committee.